BD2 domain selective BET inhibitor

oral efficacy in 3 inflammation models

from SBDD of a BD2-selective HTS hit

Science, Mar. 19, 2020

GlaxoSmithKline, Stevenage, UK

GSK620 (GlaxoSmithKline (GSK) oral in vivo BD2 domain selective BET inhibitor)


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks